Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Valagussa

Showing results (81-90 of 196) with videos related to

Pageof 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1991
Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodesA Moliterni, G Bonadonna, P Valagussa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1994
Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancerP Valagussa, A Moliterni, M Terenziani, et al.
Surgery|August 26, 1998
End points in the analysis of breast cancer survival: relapse versus death from tumorM J Edwards, G Bonadonna, P Valagussa, et al.
Cancer|June 1, 1977
The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug toleranceG Bonadonna, A Rossi, P Valagussa, et al.
Journal of the National Cancer Institute|January 1, 1981
Labeling index as a prognostic marker in non-Hodgkin's lymphomasA Costa, G Bonadonna, E Villa, et al.
Tumori|February 28, 1990
Clinically useful measures to assess the effectiveness of treatments: hints for a proper choice with special emphasis on cancer researchP Boracchi, G Mezzanotte, L Mariani, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trialU Veronesi, E Marubini, L Mariani, et al.
The New England Journal of Medicine|April 6, 1995
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-upG Bonadonna, P Valagussa, A Moliterni, et al.
Cancer|November 1, 1994
Parametric survival analysis of adjuvant therapy for stage II breast cancerJ W Gamel, R L Vogel, P Valagussa, et al.
Seminars in Oncology|March 1, 1986
CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's diseaseA Santoro, S Viviani, P Valagussa, et al.
Pageof 20

Showing results (81-90 of 196) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1991
Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodesA Moliterni, G Bonadonna, P Valagussa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1994
Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancerP Valagussa, A Moliterni, M Terenziani, et al.
Surgery|August 26, 1998
End points in the analysis of breast cancer survival: relapse versus death from tumorM J Edwards, G Bonadonna, P Valagussa, et al.
Cancer|June 1, 1977
The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug toleranceG Bonadonna, A Rossi, P Valagussa, et al.
Journal of the National Cancer Institute|January 1, 1981
Labeling index as a prognostic marker in non-Hodgkin's lymphomasA Costa, G Bonadonna, E Villa, et al.
Tumori|February 28, 1990
Clinically useful measures to assess the effectiveness of treatments: hints for a proper choice with special emphasis on cancer researchP Boracchi, G Mezzanotte, L Mariani, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trialU Veronesi, E Marubini, L Mariani, et al.
The New England Journal of Medicine|April 6, 1995
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-upG Bonadonna, P Valagussa, A Moliterni, et al.
Cancer|November 1, 1994
Parametric survival analysis of adjuvant therapy for stage II breast cancerJ W Gamel, R L Vogel, P Valagussa, et al.
Seminars in Oncology|March 1, 1986
CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's diseaseA Santoro, S Viviani, P Valagussa, et al.
Pageof 20